Itacitinib for the Prevention of IEC Therapy-Associated CRS: Results From the Two-Part Phase 2 INCB 39110-211 Study

Frigault, M. J., Maziarz, R. T., Park, J. H., Lazaryan, A., Shah, N. N., Svoboda, J., Lekakis, L. J., Reshef, R., Phillips, C. L., Burke, L., Lei, J., Pratta, M., Morariu-Zamfir, R., & DiPersio, J. F. (2025). Itacitinib for the Prevention of IEC Therapy-Associated CRS: Results From the Two-Part Phase 2 INCB 39110-211 Study. Blood Journal. https://doi.org/10.1182/blood.2024026586

Authors:

Matthew J Frigault

Richard T Maziarz

Jae H Park

Aleksandr Lazaryan

Nirav N Shah

Jakub Svoboda

Lazaros J Lekakis

Ran Reshef

Christine L Phillips

Lea Burke

Jing Lei